221 related articles for article (PubMed ID: 20658944)
21. Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Fujii M; Ohya S; Yamamura H; Imaizumi Y
J Biomol Screen; 2012 Jul; 17(6):773-84. PubMed ID: 22498908
[TBL] [Abstract][Full Text] [Related]
22. Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
Rast G; Guth BD
J Pharmacol Toxicol Methods; 2014; 70(2):182-7. PubMed ID: 25117629
[TBL] [Abstract][Full Text] [Related]
23. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
[TBL] [Abstract][Full Text] [Related]
24. hERG channel blockade by externally applied quaternary ammonium derivatives.
Choi KH; Song C; Shin D; Park S
Biochim Biophys Acta; 2011 Jun; 1808(6):1560-6. PubMed ID: 21320466
[TBL] [Abstract][Full Text] [Related]
25. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
26. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
27. Comparative evaluation of hERG potassium channel blockade by antipsychotics.
Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):457-65. PubMed ID: 17982510
[TBL] [Abstract][Full Text] [Related]
28. Thallium-sensitive fluorescent assay reveals loperamide as a new inhibitor of the potassium channel Kv10.1.
Loza-Huerta A; Milo E; Picones A; Hernández-Cruz A; Luis E
Pharmacol Rep; 2021 Dec; 73(6):1744-1753. PubMed ID: 34213738
[TBL] [Abstract][Full Text] [Related]
29. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators.
Trivedi S; Dekermendjian K; Julien R; Huang J; Lund PE; Krupp J; Kronqvist R; Larsson O; Bostwick R
Assay Drug Dev Technol; 2008 Apr; 6(2):167-79. PubMed ID: 18078380
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay.
Li Q; Rottländer M; Xu M; Christoffersen CT; Frederiksen K; Wang MW; Jensen HS
Anal Biochem; 2011 Nov; 418(1):66-72. PubMed ID: 21782781
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
[TBL] [Abstract][Full Text] [Related]
32. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A
Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647
[TBL] [Abstract][Full Text] [Related]
33. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
Zhang P; Xing J; Luo A; Feng J; Liu Z; Gao C; Ma J
J Pharm Pharmacol; 2013 Sep; 65(9):1321-8. PubMed ID: 23927470
[TBL] [Abstract][Full Text] [Related]
34. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.
Kirsch GE; Trepakova ES; Brimecombe JC; Sidach SS; Erickson HD; Kochan MC; Shyjka LM; Lacerda AE; Brown AM
J Pharmacol Toxicol Methods; 2004; 50(2):93-101. PubMed ID: 15385083
[TBL] [Abstract][Full Text] [Related]
35. Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay.
Rezazadeh S; Hesketh JC; Fedida D
J Biomol Screen; 2004 Oct; 9(7):588-97. PubMed ID: 15475478
[TBL] [Abstract][Full Text] [Related]
36. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
37. Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.
Harmer AR; Abi-Gerges N; Easter A; Woods A; Lawrence CL; Small BG; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2008; 57(1):30-41. PubMed ID: 17980627
[TBL] [Abstract][Full Text] [Related]
38. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
Carvalho JF; Louvel J; Doornbos ML; Klaasse E; Yu Z; Brussee J; IJzerman AP
J Med Chem; 2013 Apr; 56(7):2828-40. PubMed ID: 23473309
[TBL] [Abstract][Full Text] [Related]
39. hERG drug response measured in droplet bilayers.
Portonovo SA; Salazar CS; Schmidt JJ
Biomed Microdevices; 2013 Apr; 15(2):255-9. PubMed ID: 23160842
[TBL] [Abstract][Full Text] [Related]
40. A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.
Wright PD; Kanumilli S; Tickle D; Cartland J; Bouloc N; Dale T; Tresize DJ; McCloskey C; McCavera S; Blanks AM; Kettleborough C; Jerman JC
J Biomol Screen; 2015 Jul; 20(6):739-47. PubMed ID: 25656238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
